小肠肿瘤罕见原因

doi:10.11904/j.issn.1002-3070.2022.06.007

摘要/Abstract

摘要： 小肠是消化道中最长的一段,是食物消化、吸收和能量转化的主要场所,但小肠肿瘤的相关研究却鲜有报道。原发性小肠恶性肿瘤在临床少见,由于缺乏典型临床表现及有效治疗手段,导致预后极差。小肠巨大的表面积及上皮快速更新的状态与小肠肿瘤的低发病率显然相悖。小肠肿瘤较低的发病率这一科学问题已成为困扰医学科学领域的世纪之谜。本综述主要从小肠独特的生理屏障、基因调控系统、共生菌群及黏膜免疫系统四个方面剖析小肠肿瘤罕见的原因。理解小肠精密的调控机制将为研究衰老、肠道菌群及肿瘤防治提供新思路。本文基于以往研究,结合最新进展对小肠肿瘤流行病学现状、低发病率的可能原因及其对肿瘤防治的启示进行综述。

关键词: 小肠, 肿瘤, 遗传, 微生物, 免疫

Abstract: The small intestine is the longest section of the digestive tract,and it is the main place for food digestion,absorption and energy conversion.However,there are few reports on the small intestine tumors.Primary malignant tumors of the small intestine are rare in clinical practice.Due to the lack of typical clinical manifestations and effective treatment methods,the prognosis is extremely poor.The large surface area of the small intestine and the state of rapid epithelial renewal clearly contradict the low incidence of tumors.The scientific problem about the lower incidence of small tumors has become a century-old mystery that plagues the field of medical science.This review mainly analyzes the reasons for the rareness of small intestinal tumors from four aspects:the unique physiological barrier of the small intestine,gene regulatory system,commensal flora and mucosal immune system.Understanding the precise regulatory mechanism of the small intestine will provide new ideas for further studies of aging,gut microbiota,and cancer prevention and treatment.Based on previous studies and the latest research progress,this article reviews the epidemiological status of small intestine tumors,the possible reasons for the low incidence,and their implications for tumor prevention and treatment.

Key words: Small intestine, Tumor, Genetics, Microorganism, Immunity

中图分类号:

R735.3⁺2

那睿思, 郭影, 时佳琪, 郑桐森. 小肠肿瘤罕见原因[J]. 实用肿瘤学杂志, 2022, 36(6): 526-530.

NA Ruisi, GUO Ying, SHI Jiaqi, ZHENG Tongsen. Reasons why small intestinal tunors are rare[J]. Journal of Practical Oncology, 2022, 36(6): 526-530.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.06.007

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I6/526

参考文献

1 Barlow JT,Leite G,Romano AE,et al.Quantitative sequencing clarifies the role of disruptor taxa,oral microbiota,and strict anaerobes in the human small-intestine microbiome[J].Microbiome,2021,9(1):1-17.
2 Pan SY,Morrison H.Epidemiology of cancer of the small intestine[J].World J Gastrointest Oncol,2011,3(3):33-42.
3 Lowenfels AB.Why are small-bowel tumours so rare?[J].Lancet,1973,1(7793):24-26.
4 Calman KC.Why are small bowel tumours rare? An experimental model[J].Gut,1974,15(7):552-554.
5 Gelsomino F,Balsano R,De Lorenzo S,et al.Small bowel adenocarcinoma:from molecular insights to clinical management[J].Curr Oncol,2022,29(2):1223-1236.
6 Ocasio Quinones GA,Khan Suheb MZ,Woolf A.Small bowel cancer[M].Treasure Island(FL):StatPearls,2022.
7 Safatle-Ribeiro AV,Ribeiro UJr.Impact of enteroscopy on diagnosis and management of small bowel tumors[J].Chin J Cancer Res,2020,32(3):319-333.
8 Puccini A,Battaglin F,Lenz HJ.Management of advanced small bowel cancer[J].Curr Treat Options Oncol,2018,19(12):69.
9 Le DT,Durham JN,Smith KN,et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J].Science,2017,357(6349):409-413.
10 Emilsson L,Semrad C,Lebwohl B,et al.Risk of small bowel adenocarcinoma,adenomas,and carcinoids in a nationwide cohort of individuals with celiac disease[J].Gastroenterology,2020,159(5):1686-1694.
11 Latham A,Shia J,Patel Z,et al.Characterization and clinical outcomes of DNA mismatch repair-deficient small bowel adenocarcinoma[J].Clin Cancer Res,2021,27(5):1429-1437.
12 Deloose E,Janssen P,Depoortere I,et al.The migrating motor complex:control mechanisms and its role in health and disease[J].Nat Rev Gastroenterol Hepatol,2012,9(5):271-285.
13 Donaldson GP,Lee SM,Mazmanian SK.Gut biogeography of the bacterial microbiota[J].Nat Rev Microbiol,2016,14(1):20-32.
14 Bottcher A,Buttner M,Tritschler S,et al.Non-canonical Wnt/PCP signalling regulates intestinal stem cell lineage priming towards enteroendocrine and Paneth cell fates[J].Nat Cell Biol,2021,23(1):23-31.
15 Riva L,Pandiri AR,Li YR,et al.The mutational signature profile of known and suspected human carcinogens in mice[J].Nat Genet,2020,52(11):1189-1197.
16 Martincorena I,Raine KM,Gerstung M,et al.Universal patterns of selection in cancer and somatic tissues[J].Cell,2018,173(7):1823.
17 Cairns J.Mutation selection and the natural history of cancer[J].Nature,1975,255(5505):197-200.
18 Potten CS.Stem cells in gastrointestinal epithelium:numbers,characteristics and death[J].Philos Trans R Soc Lond B Biol Sci,1998,353(1370):821-830.
19 Koren E,Yosefzon Y,Ankawa R,et al.ARTS mediates apoptosis and regeneration of the intestinal stem cell niche[J].Nat Commun,2018,9(1):1-17.
20 Schepers AG,Vries R,Van Den Born M,et al.Lgr5 intestinal stem cells have high telomerase activity and randomly segregate their chromosomes[J].EMBO J,2011,30(6):1104-1109.
21 Tomasetti C,Vogelstein B.Cancer etiology.Variation in cancer risk among tissues can be explained by the number of stem cell divisions[J].Science,2015,347(6217):78-81.
22 Ogata M,Oomori T,Soga H,et al.DNA repair after DNA fragmentation in mouse small intestinal epithelial cells[J].Cell Tissue Res,2009,335(2):371-382.
23 Schrock AB,Devoe CE,Mcwilliams R,et al.Genomic profiling of small-bowel adenocarcinoma[J].JAMA Oncol,2017,3(11):1546-1553.
24 Kadosh E,Snir-Alkalay I,Venkatachalam A,et al.The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic[J].Nature,2020,586(7827):133-138.
25 Mantovani F,Collavin L,Del Sal G.Mutant p53 as a guardian of the cancer cell[J].Cell Death Differ,2019,26(2):199-212.
26 Ocvirk S,O'keefe SJD.Dietary fat,bile acid metabolism and colorectal cancer[J].Semin Cancer Biol,2021,73:347-355.
27 Mohammed AD,Mohammed Z,Roland MM,et al.Defective humoral immunity disrupts bile acid homeostasis which promotes inflammatory disease of the small bowel[J].Nat Commun,2022,13(1):1-17.
28 Roberti MP,Yonekura S,Duong CPM,et al.Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer[J].Nat Med,2020,26(6):919-931.
29 Daillere R,Vetizou M,Waldschmitt N,et al.Enterococcus hirae and barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects[J].Immunity,2016,45(4):931-943.
30 Zhang P,Liu J,Xiong B,et al.Microbiota from alginate oligosaccharide-dosed mice successfully mitigated small intestinal mucositis[J].Microbiome,2020,8(1):1-15.
31 Song M,Chan AT,Sun J.Influence of the gut microbiome,diet,and environment on risk of colorectal cancer[J].Gastroenterology,2020,158(2):322-340.
32 Fawkner-Corbett D,Antanaviciute A,Parikh K,et al.Spatiotemporal analysis of human intestinal development at single-cell resolution[J].Cell,2021,184(3):810-826.
33 Rios D,Wood MB,Li J,et al.Antigen sampling by intestinal M cells is the principal pathway initiating mucosal IgA production to commensal enteric bacteria[J].Mucosal Immunol,2016,9(4):907-916.
34 Chen H,Zhang Y,Ye AY,et al.BCR selection and affinity maturation in Peyer's patch germinal centres[J].Nature,2020,582(7812):421-425.
35 Fenton TM,Jorgensen PB,Niss K,et al.Immune profiling of human gut-associated lymphoid tissue identifies a role for isolated lymphoid follicles in priming of region-specific immunity[J].Immunity,2020,52(3):557-570.
36 Simoni Y,Fehlings M,Kloverpris HN,et al.Human innate lymphoid cell subsets possess tissue-type based heterogeneity in phenotype and frequency[J].Immunity,2017,46(1):148-161.
37 Olivares-Villagomez D,Van Kaer L.Intestinal intraepithelial lymphocytes:sentinels of the mucosal barrier[J].Trends Immunol,2018,39(4):264-275.
38 Mayassi T,Jabri B.Human intraepithelial lymphocytes[J].Mucosal Immunol,2018,11(5):1281-1289.
39 Morikawa R,Nemoto Y,Yonemoto Y,et al.Intraepithelial lymphocytes suppress intestinal tumor growth by cell-to-cell contact via CD103/E-Cadherin signal[J].Cell Mol Gastroenterol Hepatol,2021,11(5):1483-1503.
40 Biton M,Haber AL,Rogel N,et al.T helper cell cytokines modulate intestinal stem cell renewal and differentiation[J].Cell,2018,175(5):1307-1320.
41 Gronke K,Hernandez PP,Zimmermann J,et al.Interleukin-22 protects intestinal stem cells against genotoxic stress[J].Nature,2019,566(7743):249-253.
42 Lee JW,Epardaud M,Sun J,et al.Peripheral antigen display by lymph node stroma promotes T cell tolerance to intestinal self[J].Nat Immunol,2007,8(2):181-190.
43 Mohammed AD,Mohammed Z,Roland MM,et al.Defective humoral immunity disrupts bile acid homeostasis which promotes inflammatory disease of the small bowel[J].Nat Commun,2022,13(1):525.
44 Di Micco R,Krizhanovsky V,Baker D,et al.Cellular senescence in ageing:from mechanisms to therapeutic opportunities[J].Nat Rev Mol Cell Biol,2021,22(2):75-95.
45 Brooks JF 2nd,Behrendt CL,Ruhn KA,et al.The microbiota coordinates diurnal rhythms in innate immunity with the circadian clock[J].Cell,2021,184(16):4154-4167.
46 Sbierski-Kind J,Grenkowitz S,Schlickeiser S,et al.Effects of caloric restriction on the gut microbiome are linked with immune senescence[J].Microbiome,2022,10(1):1-21.
47 Fu A,Yao B,Dong T,et al.Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer[J].Cell,2022,185(8):1356-1372.
48 Guo W,Zhang C,Wang X,et al.Resolving the difference between left-sided and right-sided colorectal cancer by single-cell sequencing[J].JCI Insight,2022,7(1):1-18.

[1]	王嘉倍, 张运广, 刘连新. 免疫治疗联合分子靶向药物治疗中晚期肝细胞癌的临床疗效及安全性分析:一项单臂回顾性研究[J]. 实用肿瘤学杂志, 2022, 36(6): 489-494.
[2]	杨菊, 刘芹, 刘宝瑞, 魏嘉. 胃癌相关癌睾抗原筛选与免疫浸润分析[J]. 实用肿瘤学杂志, 2022, 36(6): 495-501.
[3]	巩芮宁, 任贺. 胰腺导管腺癌免疫治疗研究现状和展望[J]. 实用肿瘤学杂志, 2022, 36(6): 502-506.
[4]	曹文杰, 魏瑗, 邝栋明. 肿瘤浸润B细胞与免疫治疗[J]. 实用肿瘤学杂志, 2022, 36(6): 507-512.
[5]	张玥, 汪越, 魏嘉. SHP2作为抗肿瘤治疗靶点的价值及其在肿瘤免疫治疗中的应用[J]. 实用肿瘤学杂志, 2022, 36(6): 513-519.
[6]	程思远, 韩子翰, 郭晓欢, 沈琳, 彭智. 肠道菌群与肿瘤免疫治疗疗效及不良反应关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 520-525.
[7]	杨磊, 张正凤, 王大榛, 娄长杰. 基于真实世界的晚期食管鳞癌一线标准化疗联合免疫检查点抑制剂对比标准化疗的回顾性对照研究[J]. 实用肿瘤学杂志, 2022, 36(6): 538-543.
[8]	徐子涵, 于国华, 聂玉辉, 孙蒙蒙, 丰慧, 刘淑真. 外周血标志物对晚期非小细胞肺癌免疫相关不良反应的预测作用及与生存结局的相关性分析[J]. 实用肿瘤学杂志, 2022, 36(6): 544-550.
[9]	王馨艺, 路一平（综述, 孙峥嵘. m6A RNA甲基化修饰影响恶性肿瘤及肿瘤干细胞生物学特性的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 551-555.
[10]	张淑敏, 张弓. ILC2s在肿瘤免疫调控中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 566-569.
[11]	朱开彬, 贺长军, 陈澜涛, 孔祥龙, 赵苏, 徐世东. TAM通过PLGF/Flt-1和TGF-β1通路促进非小细胞肺癌生长和肿瘤血管异生的研究[J]. 实用肿瘤学杂志, 2022, 36(5): 391-397.
[12]	王钦, 刘军杰, 陆秀鑫, 吴雅菲, 张文皓. 基于铁死亡的纳米联合疗法在恶性肿瘤治疗中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 429-434.
[13]	黄永平, 李梦洁, 孙玉芳, 项涛. 细菌生物膜在肿瘤生物学进程及治疗应用中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 440-444.
[14]	何晓晴, 柯鹏, 张新友. BCL-2抑制剂在血液恶性肿瘤中的靶向治疗应用及作用机制[J]. 实用肿瘤学杂志, 2022, 36(5): 452-457.
[15]	李雄, 姜文凯, 郎泽昆, 芮少珍. 肿瘤相关中性粒细胞与胰腺癌关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 458-462.